Literature DB >> 23358894

Fibroblast growth factor 21: a novel metabolic regulator from pharmacology to physiology.

Huating Li1, Jing Zhang, Weiping Jia.   

Abstract

Fibroblast growth factor 21 (FGF21) is a member of the fibroblast growth factor family. It actually functions as endocrine hormones but does not regulate cell growth and differentiation. It is demonstrated that FGF21 acts on multiple tissue to coordinate carbohydrate and lipid metabolism, including enhancing insulin sensitivity, decreasing triglyceride concentrations, causing weight loss, ameliorating obesity-associated hyperglycemia and hyperlipidemia. Moreover, FGF21 also plays important roles in some physiological processes, such as fasting and feeding, growth hormone axis and thermogenic function of brown adipose tissue. Clinical relevance of FGF21 in humans is still unclear, and the basis and consequences of increased FGF21 in metabolic disease remain to be determined. Both the pharmacological actions and physiological roles make FGF21 attractive drug candidates for treating metabolic disease, but some questions remain to be answered. This article concentrates on recent advances in our understanding of FGF21.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23358894     DOI: 10.1007/s11684-013-0244-8

Source DB:  PubMed          Journal:  Front Med        ISSN: 2095-0217            Impact factor:   4.592


  55 in total

Review 1.  FGF23 is a hormone-regulating phosphate metabolism--unique biological characteristics of FGF23.

Authors:  Seiji Fukumoto; Takeyoshi Yamashita
Journal:  Bone       Date:  2007-01-04       Impact factor: 4.398

Review 2.  Nutritional regulation of the insulin-like growth factors.

Authors:  J P Thissen; J M Ketelslegers; L E Underwood
Journal:  Endocr Rev       Date:  1994-02       Impact factor: 19.871

3.  Evaluation of concentrations of FGF-21 - a new adipocytokine in type 2 diabetes.

Authors:  Beata Matuszek; Monika Lenart-Lipińska; Dariusz Duma; Janusz Solski; Andrzej Nowakowski
Journal:  Endokrynol Pol       Date:  2010 Jan-Feb       Impact factor: 1.582

4.  Daily physical activity, fasting glucose, uric acid, and body mass index are independent factors associated with serum fibroblast growth factor 21 levels.

Authors:  Daniel Cuevas-Ramos; Paloma Almeda-Valdes; Francisco J Gómez-Pérez; Clara Elena Meza-Arana; Ivette Cruz-Bautista; Olimpia Arellano-Campos; Mariana Navarrete-López; Carlos A Aguilar-Salinas
Journal:  Eur J Endocrinol       Date:  2010-06-21       Impact factor: 6.664

5.  Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23.

Authors: 
Journal:  Nat Genet       Date:  2000-11       Impact factor: 38.330

6.  Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity.

Authors:  M Mraz; M Bartlova; Z Lacinova; D Michalsky; M Kasalicky; D Haluzikova; M Matoulek; I Dostalova; V Humenanska; M Haluzik
Journal:  Clin Endocrinol (Oxf)       Date:  2008-12-11       Impact factor: 3.478

Review 7.  Fibroblast growth factor-21 as a therapeutic agent for metabolic diseases.

Authors:  Alexei Kharitonenkov; Armen B Shanafelt
Journal:  BioDrugs       Date:  2008       Impact factor: 5.807

8.  PPARalpha is a key regulator of hepatic FGF21.

Authors:  Thomas Lundåsen; Mary C Hunt; Lisa-Mari Nilsson; Sabyasachi Sanyal; Bo Angelin; Stefan E H Alexson; Mats Rudling
Journal:  Biochem Biophys Res Commun       Date:  2007-06-21       Impact factor: 3.575

9.  Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans.

Authors:  Xinmei Zhang; Dennis C Y Yeung; Michal Karpisek; David Stejskal; Zhi-Guang Zhou; Feng Liu; Rachel L C Wong; Wing-Sun Chow; Annette W K Tso; Karen S L Lam; Aimin Xu
Journal:  Diabetes       Date:  2008-02-05       Impact factor: 9.461

10.  Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance.

Authors:  Alberto O Chavez; Marjorie Molina-Carrion; Muhammad A Abdul-Ghani; Franco Folli; Ralph A Defronzo; Devjit Tripathy
Journal:  Diabetes Care       Date:  2009-06-01       Impact factor: 19.112

View more
  29 in total

1.  Transcriptome Analysis of K-877 (a Novel Selective PPARα Modulator (SPPARMα))-Regulated Genes in Primary Human Hepatocytes and the Mouse Liver.

Authors:  Sana Raza-Iqbal; Toshiya Tanaka; Motonobu Anai; Takeshi Inagaki; Yoshihiro Matsumura; Kaori Ikeda; Akashi Taguchi; Frank J Gonzalez; Juro Sakai; Tatsuhiko Kodama
Journal:  J Atheroscler Thromb       Date:  2015-06-04       Impact factor: 4.928

2.  Additive protection by LDR and FGF21 treatment against diabetic nephropathy in type 2 diabetes model.

Authors:  Minglong Shao; Lechu Yu; Fangfang Zhang; Xuemian Lu; Xiaokun Li; Peng Cheng; Xiufei Lin; Luqing He; Shunzi Jin; Yi Tan; Hong Yang; Chi Zhang; Lu Cai
Journal:  Am J Physiol Endocrinol Metab       Date:  2015-05-12       Impact factor: 4.310

3.  An engineered FGF21 variant, LY2405319, can prevent non-alcoholic steatohepatitis by enhancing hepatic mitochondrial function.

Authors:  Ju Hee Lee; Yea Eun Kang; Joon Young Chang; Ki Cheol Park; Hyeon-Woo Kim; Jung Tae Kim; Hyun Jin Kim; Hyon-Seung Yi; Minho Shong; Hyo Kyun Chung; Koon Soon Kim
Journal:  Am J Transl Res       Date:  2016-11-15       Impact factor: 4.060

Review 4.  The role of the Nrf2/Keap1 pathway in obesity and metabolic syndrome.

Authors:  Zhiguo Zhang; Shanshan Zhou; Xin Jiang; Yue-Hui Wang; Fengsheng Li; Yong-Gang Wang; Yang Zheng; Lu Cai
Journal:  Rev Endocr Metab Disord       Date:  2015-03       Impact factor: 6.514

5.  Single-Arm 8-Week Ad Libitum Self-Prepared Paleo Diet Reduces Cardiometabolic Disease Risk Factors in Overweight Adults.

Authors:  Melissa M Markofski; Kristofer Jennings; Chad Dolan; Natalie A Davies; Emily C LaVoy; Edward J Ryan; Andres E Carrillo
Journal:  Am J Lifestyle Med       Date:  2019-08-02

Review 6.  Promising therapies for treatment of nonalcoholic steatohepatitis.

Authors:  Mazen Noureddin; Alice Zhang; Rohit Loomba
Journal:  Expert Opin Emerg Drugs       Date:  2016-08-28       Impact factor: 4.191

Review 7.  Minireview: Roles of Fibroblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic Diseases.

Authors:  Fangfang Zhang; Lechu Yu; Xiufei Lin; Peng Cheng; Luqing He; Xiaokun Li; Xuemian Lu; Yi Tan; Hong Yang; Lu Cai; Chi Zhang
Journal:  Mol Endocrinol       Date:  2015-08-26

8.  Effects of central FGF21 infusion on the hypothalamus-pituitary-thyroid axis and energy metabolism in rats.

Authors:  Umit Yilmaz; Suat Tekin; Mehmet Demir; Yilmaz Cigremis; Suleyman Sandal
Journal:  J Physiol Sci       Date:  2018-02-07       Impact factor: 2.781

9.  Fibroblast Growth Factor 21 (Fgf21) Gene Expression Is Elevated in the Liver of Mice Fed a High-Carbohydrate Liquid Diet and Attenuated by a Lipid Emulsion but Is Not Upregulated in the Liver of Mice Fed a High-Fat Obesogenic Diet.

Authors:  Lei Hao; Kuan-Hsun Huang; Kyoko Ito; Sudathip Sae-Tan; Joshua D Lambert; A Catharine Ross
Journal:  J Nutr       Date:  2016-01-13       Impact factor: 4.798

10.  FGF21 inhibits apolipoprotein(a) expression in HepG2 cells via the FGFR1-ERK1/2-Elk-1 pathway.

Authors:  Xiaolong Lin; Guohua Li; Xinglan He; Xiaofeng Ma; Kai Zhang; Hai Zhang; Gaofeng Zeng; Zuo Wang
Journal:  Mol Cell Biochem       Date:  2014-04-04       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.